Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 2 , Pages 98-104 , February 2009

Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study

  • G. de Simone

      Affiliations

    • Weill-Cornell Medical College, New York, NY, USA
    • Federico II University, Naples, Italy
    • Corresponding Author InformationCorresponding author: Department of Clinical and Experimental Medicine, Federico II University Hospital, v.S.Pansini 5, 80131 Naples, Italy. Tel.: +39 081 746 2013.
    • ,
  • R.B. Devereux

      Affiliations

    • Weill-Cornell Medical College, New York, NY, USA
    • ,
  • M. Chinali

      Affiliations

    • Federico II University, Naples, Italy
    • ,
  • M.J. Roman

      Affiliations

    • Weill-Cornell Medical College, New York, NY, USA
    • ,
  • E.T. Lee

      Affiliations

    • University of Oklahoma, Oklahoma City, OK, USA
    • ,
  • H.E. Resnick

      Affiliations

    • Medstar Research Institute, Washington, DC, USA
    • ,
  • B.V. Howard

      Affiliations

    • Medstar Research Institute, Washington, DC, USA

Received 9 January 2008 ,Revised 6 April 2008 ,Accepted 7 April 2008.

References 

  1. WHO . Definition of metabolic syndrome in definition, diagnosis and classification of diabetes and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneve: World Health Organization – Department of Noncommunicable Disease Surveillance; 1999;WHO/NCD/NCS/99.2
  2. Third Report of the National Cholesterol Education Program (NCEP) . Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3421
  3. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364–376
  4. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–252
  5. Alberti G. Introduction to the metabolic syndrome. Eur Heart J Suppl. 2005;7:3–5
  6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  7. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245–1250
  8. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817–1822
  9. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2007;17:473–481
  10. Mule G, Cottone S, Mongiovi R, Cusimano P, Mezzatesta G, Seddio G, et al. Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis. 2006;16:54–59
  11. Tartan Z, Ozer N, Uyarel H, Akgul O, Gul M, Cetin M, et al. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction. Nutr Metab Cardiovasc Dis. 2007;[Epub ahead of print]
  12. Gotto AM, Blackburn GL, Dailey GE, Garber AJ, Grundy SM, Sobel BE, et al. The metabolic syndrome: a call to action. Coron Artery Dis. 2006;17:77–80
  13. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  14. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304
  15. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts?. Circulation. 2003;108:1546–1551
  16. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88:1444–1455
  17. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care. 2007;30:1851–1856
  18. de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens. 2007;21:625–632
  19. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004;93:40–44
  20. Schillaci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G, et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension. 2005;45:1078–1082
  21. Iannuzzi A, De Michele M, Bond MG, Sacchetti L, Fortunato G, Salvatore F, et al. Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the “Progetto ATENA” study). Am J Cardiol. 2005;96:1162–1165
  22. Lee ET, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, et al. The Strong Heart Study – a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;136:1141–1155
  23. Howard BV, Lee ET, Yeh JL, Go O, Fabsitz RR, Devereux RB, et al. Hypertension in adult American Indians. The Strong Heart Study. Hypertension. 1996;28:256–264
  24. Welty TK, Lee ET, Yeh J, Cowan LD, Go O, Fabsitz RR, et al. Cardiovascular disease risk factors among American Indians. The Strong Heart Study. Am J Epidemiol. 1995;142:269–287
  25. Lee ET, Cowan LD, Welty TK, Sievers M, Howard WJ, Oopik A, et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45–74years, 1984–1988. The Strong Heart Study. Am J Epidemiol. 1998;147:995–1008
  26. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000;101:2271–2276
  27. Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation. 1999;99:2389–2395
  28. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health. Obes Res. 1998;6:51S–209S
  29. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997;20:S1–S70
  30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  31. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  32. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251–1260
  33. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy The Strong Heart Study. Am J Hypertens. 2005;18:191–196
  34. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens. 2005;18:191–196
  35. Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study. Am J Hypertens. 1997;10:705–713
  36. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–47
  37. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22:1991–1998
  38. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A, et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med. 2005;257:454–460
  39. Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW, et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2005;112:819–827
  40. Cuspidi C, Meani S, Valerio C, Sala C, Fusi V, Zanchetti A, et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens. 2007;20:296–303
  41. Davis CL, Kapuku G, Snieder H, Kumar M, Treiber FA. Insulin resistance syndrome and left ventricular mass in healthy young people. Am J Med Sci. 2002;324:72–75
  42. Suman OE, Hasten D, Turner MJ, Rinder MR, Spina RJ, Ehsani AA. Enhanced inotropic response to dobutamine in strength-trained subjects with left ventricular hypertrophy. J Appl Physiol. 2000;88:534–539
  43. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis. 2007;17:125–139
  44. Devereux RB, Roman MJ, Liu JE, Lee ET, Wang W, Fabsitz RR, et al. An appraisal of echocardiography as an epidemiological tool. The Strong Heart Study. Ann Epidemiol. 2003;13:238–244
  45. Giampaoli S, Palmieri L, Mattiello A, Panico S. Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases. Nutr Metab Cardiovasc Dis. 2005;15:79–85

PII: S0939-4753(08)00078-1

doi: 10.1016/j.numecd.2008.04.001

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 2 , Pages 98-104 , February 2009

Article Tools

* Image Usage & Resolution